Atherosclerosis is an inflammatory disease with multiple underlying metabolic and physical risk factors including disturbed flow (d-flow), hypercholesterolemia, hypertension and diabetes. However, the mechanisms by which these pro-atherogenic risk factors synergize, leading to initiation and progression of atherosclerosis are still unclear. Recently, we found that BMP Receptor II (BMPR2) plays an unexpected role as an anti- inflammatory and anti-atherogenic protein in endothelial cells. We found that BMPR2 expression was progressively lost as atherosclerosis advances in human coronary arteries. We also found that multiple pro- atherogenic stimuli [d-flow, angiotensin II (Ang II), hypercholesterolemia and TNF?], significantly downregulated BMPR2 expression in endothelium, while anti-atherogenic stimuli such as stable flow (s-flow) upregulated its expression in vivo and in vitro. This suggests that there may be a common mechanism by which pro-atherogenic factors downregulate BMPR2 expression and that protecting it from risk factors or restoring its expression could be a novel avenue for prevention and treatment of atherosclerosis. This application is designed to address these questions to develop a novel therapeutic strategy to prevent the loss of BMPR2 expression as well as to investigate the subsequent mechanism by which it induces endothelial inflammation. Emerging evidence demonstrates that BMPR2 expression can be regulated by microRNAs, although their role in inflammation and atherosclerosis is unclear. Our preliminary studies based on miRNA arrays obtained from mouse arteries subjected to d-flow (by partial carotid ligation) or Ang II have identified 6 miRNAs (miR-17, -21, -25, -93, -106 and -181) as potential pro-atherogenic miRNAs (athero-miRs) that could directly target BMPR2. Current methods to inhibit miRNAs such as anti-miRs affect their target genes (~hundreds) indiscriminately, potentially causing both desired and unwanted effects. Here, we will use a novel approach using ?target site blockers (TSBs)? to avoid the indiscriminate effects of the current methods. Our overarching hypothesis is that pro-atherogenic factors increase endothelial expression of the athero-miRs that directly downregulate BMPR2, which in turn triggers endothelial inflammation and atherosclerosis. We further propose that BR2-TSBs would protect BMPR2 from the athero-miRs, preserving its constitutive anti- inflammatory and anti-atherogenic role without affecting other athero-miR targets. This hypothesis will be tested using two pro-atherogenic conditions (d-flow and Ang II) in vitro (endothelial cells [ECs]) and in vivo.
Aim 1 will determine the functional role of athero-miRs on BMPR2 expression by d-flow and Ang II in ECs in vitro and in vivo.
In Aim 2, we will design BR2-TSBs to prevent BMPR2 downregulation by athero-miRs in ECs in vitro and in vivo.
Aim 3 will determine the therapeutic potential of BR2-TSBs in atherosclerosis in ApoE-/- mice.
Aim 4 will test the hypothesis that loss of BMPR2 leads to ?unleashing? of BMPR2 tail-binding proteins, resulting in endothelial inflammation and atherosclerosis.

Public Health Relevance

Atherosclerosis, the major cause of heart attack and stroke, occurs in response to multiple risk factors such as high cholesterol and diabetes in arterial branches or curved areas where blood flow is unstable. We recently discovered that many of these risk factors commonly reduce expression of a protein called bone morphogenic protein receptor 2 (BMPR2) in blood vessel cells, which in turn induces vascular inflammation and eventual atherosclerosis by unknown mechanisms. This application is designed to determine the mechanism by which BMPR2 expression is regulated by microRNAs and how loss of BMPR2 induces atherosclerosis, and may lead to novel therapeutics that could prevent and treat atherosclerosis.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL095070-07
Application #
9100843
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Project Start
Project End
Budget Start
2016-05-01
Budget End
2017-04-30
Support Year
7
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Emory University
Department
Type
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Paredes, Felipe; Suster, Izabela; Martin, Alejandra San (2018) Poldip2 takes a central role in metabolic reprograming. Oncoscience 5:130-131
Lee, Grace Sanghee; Salazar, Hector F; Joseph, Giji et al. (2018) Osteopontin isoforms differentially promote arteriogenesis in response to ischemia via macrophage accumulation and survival. Lab Invest :
Simmons, Craig A; Jo, Hanjoong (2018) Editorial: Special Issue on Heart Valve Mechanobiology : New Insights into Mechanical Regulation of Valve Disease and Regeneration. Cardiovasc Eng Technol 9:121-125
Williams, Holly C; Ma, Jing; Weiss, Daiana et al. (2018) The cofilin phosphatase slingshot homolog 1 restrains angiotensin II-induced vascular hypertrophy and fibrosis in vivo. Lab Invest :
Yeligar, Samantha M; Kang, Bum-Yong; Bijli, Kaiser M et al. (2018) PPAR? Regulates Mitochondrial Structure and Function and Human Pulmonary Artery Smooth Muscle Cell Proliferation. Am J Respir Cell Mol Biol 58:648-657
Vukelic, Sasa; Xu, Qian; Seidel-Rogol, Bonnie et al. (2018) NOX4 (NADPH Oxidase 4) and Poldip2 (Polymerase ?-Interacting Protein 2) Induce Filamentous Actin Oxidation and Promote Its Interaction With Vinculin During Integrin-Mediated Cell Adhesion. Arterioscler Thromb Vasc Biol 38:2423-2434
Hernandes, Marina S; Lassègue, Bernard; Hilenski, Lula L et al. (2018) Polymerase delta-interacting protein 2 deficiency protects against blood-brain barrier permeability in the ischemic brain. J Neuroinflammation 15:45
Okwan-Duodu, Derick; Hansen, Laura; Joseph, Giji et al. (2018) Impaired Collateral Vessel Formation in Sickle Cell Disease. Arterioscler Thromb Vasc Biol 38:1125-1133
Hu, Shuhong; Liu, Yifei; You, Tao et al. (2018) Vascular Semaphorin 7A Upregulation by Disturbed Flow Promotes Atherosclerosis Through Endothelial ?1 Integrin. Arterioscler Thromb Vasc Biol 38:335-343
Heath, Jack M; Fernandez Esmerats, Joan; Khambouneheuang, Lucky et al. (2018) Mechanosensitive microRNA-181b Regulates Aortic Valve Endothelial Matrix Degradation by Targeting TIMP3. Cardiovasc Eng Technol 9:141-150

Showing the most recent 10 out of 125 publications